Regulation of Ca++ signaling by the PDK 2 gene product

PDK 2 基因产物对 Ca 信号传导的调节

基本信息

项目摘要

DESCRIPTION (provided by applicant): The function(s) of the genes responsible for the vast majority of cases of autosomal dominant polycystic kidney disease (ADPKD) are unknown. Based on sequence analysis, the gene product of the polycystic kidney disease gene 1 (PKD1) has been proposed to encode a protein with a role in cell-cell and/or cell - extracellular matrix interactions while PKD2 is thought to function as a cation channel. We have shown that PKD2 physically associated with PKD1 and only in the presence of PKD1, PKD2 was able to form a Ca++ permeable cation channel. In addition to PKD 1, PKD2 was also able to associate with the transient receptor potential channel 1 (TRPC1). We now show that TRPC1 has a widespread distribution in epithelial structures, primarily the ductal cells of the kidney and liver. TRPC 1 was shown to enhance Ca++ entry in response to store depletion (or capacitative Ca++ entry, CCE). CCE is the major route by which non-excitable cells regulate their intracellular Ca++ concentration. Among the many cellular functions regulated by CCE, regulation of cAMP accumulation is a well-characterized and specific physiological target of CCE. Notably, the involvement of cAMP in cyst formation in kidney and liver epithelial cells has been well established. We propose that PKD1, PKD2 and TRPC1 assemble to a functional complex to enhance CCE. Naturally occurring mutations in PKD2 may result in the disruption of this complex and thereby in alterations in CCE. We will test our model by showing the existence of an endogenous complex and identifying protein-protein interactions responsible for complex assembly. Next, we will measure CCE in cells transfected with PKD1, PKD2 and TRPC1. We will evaluate an effect of PKD2 on CCE by introducing dominant negative constructs of PKD2 in cell lines that endogenously express PKD1, PKD2 and TRPC1 and testing whether wild type or mutant PKD2 can regulate cAMP accumulation in kidney epithelial cells. Our ultimate goal is to develop a biologically significant system that would allow us to probe the mechanisms by which pathogenic mutations in PKD2 alter its normal function, and to design therapeutic interventions in diseases such as ADPKD.
描述(由申请人提供):负责基因的功能 对于绝大多数常染色体显性遗传性多囊肾病病例, (ADPKD)未知。基于序列分析, 已提出多囊肾病基因1(PKD 1)编码蛋白质 在细胞-细胞和/或细胞-细胞外基质相互作用中起作用, PKD2被认为是阳离子通道。我们已经证明PKD 2 与PKD 1有身体上的联系,只有在PKD 1存在的情况下,PKD 2才能 以形成Ca ++可渗透的阳离子通道。除PKD 1外,PKD 2也是 能够与瞬时受体电位通道1(TRPC 1)结合。我们 现在显示TRPC 1在上皮结构中具有广泛的分布, 主要是肾脏和肝脏的导管细胞。TRPC 1被证明可以增强 Ca ++内流对钙池耗竭的响应(或容量性Ca ++内流,CCE)。 CCE是非兴奋性细胞调节其细胞周期的主要途径。 细胞内Ca ++浓度。在调节的许多细胞功能中, 通过CCE,cAMP积累的调节是一个充分表征的和特异性的, CCE的生理靶点。值得注意的是,cAMP参与囊肿形成, 在肾脏和肝脏上皮细胞中的作用已经很好地确立。我们建议 PKD 1、PKD 2和TRPC 1组装成功能复合物以增强CCE。自然 PKD2中发生的突变可能导致这种复合物的破坏, 从而改变CCE。我们将通过证明存在 和鉴定蛋白质间的相互作用 负责复杂的装配。接下来,我们将测量细胞中的CCE 用PKD 1、PKD 2和TRPC 1转染。我们将评估PKD 2对 CCE通过在细胞系中引入PKD 2的显性阴性构建体, 内源性表达PKD 1、PKD 2和TRPC 1,并测试野生型或 突变PKD 2可调节肾上皮细胞中cAMP的积累。我们 最终目标是开发一个具有生物学意义的系统, 我们探索PKD 2致病性突变改变其功能的机制。 正常功能,并设计疾病的治疗干预措施, ADPKD。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Leonidas Tsiokas其他文献

Leonidas Tsiokas的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Leonidas Tsiokas', 18)}}的其他基金

Ciliary Disassembly, a modifier of Autosomal Dominant Polycystic Kidney Disease
纤毛分解,常染色体显性多囊肾病的修饰因子
  • 批准号:
    10365921
  • 财政年份:
    2021
  • 资助金额:
    $ 17.28万
  • 项目类别:
Ciliary Disassembly, a modifier of Autosomal Dominant Polycystic Kidney Disease
纤毛分解,常染色体显性多囊肾病的修饰因子
  • 批准号:
    10094363
  • 财政年份:
    2021
  • 资助金额:
    $ 17.28万
  • 项目类别:
Ciliary Disassembly, a modifier of Autosomal Dominant Polycystic Kidney Disease
纤毛分解,常染色体显性多囊肾病的修饰因子
  • 批准号:
    10549844
  • 财政年份:
    2021
  • 资助金额:
    $ 17.28万
  • 项目类别:
Regulation of calcium signaling by the PKD2 gene product
PKD2 基因产物对钙信号传导的调节
  • 批准号:
    9927634
  • 财政年份:
    2017
  • 资助金额:
    $ 17.28万
  • 项目类别:
Regulation of calcium signaling by the PKD2 gene product
PKD2 基因产物对钙信号传导的调节
  • 批准号:
    8110446
  • 财政年份:
    2010
  • 资助金额:
    $ 17.28万
  • 项目类别:
Regulation of Ca++ signaling by the PDK 2 gene product
PDK 2 基因产物对 Ca 信号传导的调节
  • 批准号:
    6828298
  • 财政年份:
    2002
  • 资助金额:
    $ 17.28万
  • 项目类别:
Regulation of Ca++ signaling by the PDK 2 gene product
PDK 2 基因产物对 Ca 信号传导的调节
  • 批准号:
    6430599
  • 财政年份:
    2002
  • 资助金额:
    $ 17.28万
  • 项目类别:
Regulation of calcium signaling by the PKD2 gene product
PKD2 基因产物对钙信号传导的调节
  • 批准号:
    8670724
  • 财政年份:
    2002
  • 资助金额:
    $ 17.28万
  • 项目类别:
Regulation of Ca++ signaling by the PDK 2 gene product
PDK 2 基因产物对 Ca 信号传导的调节
  • 批准号:
    6940582
  • 财政年份:
    2002
  • 资助金额:
    $ 17.28万
  • 项目类别:
Regulation of calcium signaling by the PKD2 gene product
PKD2 基因产物对钙信号传导的调节
  • 批准号:
    8107253
  • 财政年份:
    2002
  • 资助金额:
    $ 17.28万
  • 项目类别:

相似海外基金

L-type Calcium Channel SNP rs1006737: characterizing the genetic risks in MUD (Methamphetamine Use Disorder)
L 型钙通道 SNP rs1006737:表征 MUD(甲基苯丙胺使用障碍)的遗传风险
  • 批准号:
    10668210
  • 财政年份:
    2023
  • 资助金额:
    $ 17.28万
  • 项目类别:
Development of a Novel Calcium Channel Therapeutic for the Treatment of Asthma
开发治疗哮喘的新型钙通道疗法
  • 批准号:
    10603554
  • 财政年份:
    2023
  • 资助金额:
    $ 17.28万
  • 项目类别:
Development of a Novel Calcium Channel Therapeutic for Opioid Use Disorder
开发一种治疗阿片类药物使用障碍的新型钙通道疗法
  • 批准号:
    10684558
  • 财政年份:
    2023
  • 资助金额:
    $ 17.28万
  • 项目类别:
Novel Tools to Probe Trafficking and Function of Calcium Channel Signaling Complexes in Heart
探测心脏钙通道信号复合物的运输和功能的新工具
  • 批准号:
    10628914
  • 财政年份:
    2023
  • 资助金额:
    $ 17.28万
  • 项目类别:
Development of a Novel Medication for Alcohol Use Disorder with an Active IND Dual Inhibitor of T-Type Calcium Channel and Soluble Epoxide Hydrolase
使用 T 型钙通道和可溶性环氧化物水解酶的活性 IND 双重抑制剂开发治疗酒精使用障碍的新型药物
  • 批准号:
    10815882
  • 财政年份:
    2023
  • 资助金额:
    $ 17.28万
  • 项目类别:
Mechanisms of L-type Calcium Channel Regulation in Heart Health and Disease
L 型钙通道在心脏健康和疾病中的调节机制
  • 批准号:
    10734121
  • 财政年份:
    2023
  • 资助金额:
    $ 17.28万
  • 项目类别:
Structure-Function of Calcium Channel Complexes in Cardiac Physiology and Disease
钙通道复合物在心脏生理和疾病中的结构-功能
  • 批准号:
    10628911
  • 财政年份:
    2023
  • 资助金额:
    $ 17.28万
  • 项目类别:
Research Initiation Award: Defining the role of DJ-1 in regulating L-type voltage-dependent calcium channel expression in neuronal plasticity
研究启动奖:定义 DJ-1 在调节神经元可塑性中 L 型电压依赖性钙通道表达中的作用
  • 批准号:
    2200474
  • 财政年份:
    2022
  • 资助金额:
    $ 17.28万
  • 项目类别:
    Standard Grant
Design and Preclinical Development of First-in-Class Selective T-type Calcium Channel Blockers for Chronic Pain
用于治疗慢性疼痛的一流选择性 T 型钙通道阻滞剂的设计和临床前开发
  • 批准号:
    452107
  • 财政年份:
    2021
  • 资助金额:
    $ 17.28万
  • 项目类别:
    Operating Grants
Preventing the Calcium Channel Blocker – Lower Extremity Edema – Loop Diuretic Prescribing Cascade in Older Adults
预防钙通道阻滞剂 – 下肢水肿 – 老年人袢利尿剂处方级联
  • 批准号:
    10399417
  • 财政年份:
    2021
  • 资助金额:
    $ 17.28万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了